Observed Signal · Oct 29, 2026 · Earnings Report · Source: Retail-News · Impact: 1/5 · Sentiment: Positive
Redcare Pharmacy Q3 Revenue Up 18%, E-Prescription Business Grows
Redcare Pharmacy, the online pharmacy group, reported a strong third quarter 2026, with revenue increasing 18% to €847 million. The main growth driver was the prescription drug business in Germany, which grew 56% to €197 million. Group-wide Rx revenue increased 31% to €358 million. Adjusted EBITDA rose 68% to €28.7 million, with the margin improving to 3.4%. The company achieved a net profit of €1 million for the second consecutive quarter. Active customers grew by 11% year-over-year to 15.2 million, with 500,000 added in Q3 alone. Despite a slight decline in gross margin to 21.8%, the company benefited from lower distribution costs and marketing spend. The DACH region's adjusted EBITDA margin improved to 4.2%. Management confirmed the 2026 guidance: group revenue growth of 16-18% and adjusted EBITDA margin of 2.5-3.0%.
This is a financial earnings report from an online pharmacy, which is not core to the AdTech/MarTech industry. The company's marketing and advertising strategies are not discussed in sufficient depth to warrant higher importance. The news is relevant only tangentially to e-commerce and digital health retail.
Track Real-Time Earnings Report Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Redcare Pharmacy's Q3 2026 revenue increased 18% year-over-year to €847 million.
- Rx revenue in Germany grew 56% to €197 million; group-wide Rx revenue rose 31% to €358 million.
- Adjusted EBITDA jumped 68% to €28.7 million, with margin improving to 3.4%.
- Active customers reached 15.2 million, up 11% year-over-year; 500,000 added in Q3.
- Full-year 2026 guidance confirmed: revenue growth of 16-18%, adjusted EBITDA margin of 2.5-3.0%.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Redcare Pharmacy Raises 2026 Guidance on Strong Rx Business
Redcare Pharmacy, a German online pharmacy, has raised its full-year 2026 guidance for the second time, driven by strong growth in its prescription (Rx) business in Germany. The company now expects Rx revenue of €730-760 million, up from a previous forecast of €680-720 million, representing growth of 45-51% year-over-year. Group revenue growth is now projected at 16-18%, up from 15-17%. This follows a strong third quarter, with German Rx sales up 56% year-over-year and September alone up 51%. The non-Rx business is stabilizing after a weak July, with growth expected at 10-12%. The adjusted EBITDA margin forecast remains at 2.5-3.0%. Customer satisfaction remains high, with an e-Rx NPS of 80 points in August, six points above last year. Full Q3 results will be published on October 29, 2026.
Redcare Secures Digital E-Prescription Access with PoPP and Health ID
The German e-prescription infrastructure is advancing with gematik's new preliminary specifications for the 'Proof of Patient Presence' (PoPP), which will enable smartphone-based verification via the Health ID from September 2027. Redcare Pharmacy, a major online pharmacy, sees this as a secure digital access route, complementing existing CardLink and future EUDI wallet options. The migration from CardLink to PoPP will involve a parallel operation phase, with Redcare expecting a license extension until March 2028. The company's Rx business is growing significantly, with 2025 revenue up 24.1% to €2.9 billion and German Rx sales nearly doubling. PoPP Stage 1 launched in July 2026 in a model region, with smartphone check-in planned for Stage 2. Redcare is also transitioning to a new CEO in October 2026, making PoPP migration a strategic priority.
DocMorris Q3 Revenue Up, Lifts 2026 Outlook
Swiss online pharmacy DocMorris reported a strong third quarter of 2026, with revenue growing 21.5% to CHF 342.7 million. The Rx (prescription) business surged 78.3% year-over-year, driven by strong demand for digital health services. The company reached adjusted EBITDA breakeven earlier than planned, posting CHF 0.6 million. As a result, DocMorris raised its full-year 2026 guidance, now expecting revenue growth of 12.5-15% and an adjusted EBITDA better than minus CHF 10 million. The digital services segment, including TeleClinic, retail media, and marketplace, grew 46.1% to CHF 13.9 million. Active customers rose to 13.1 million. The company also refinanced a convertible bond, extending maturity to 2031.
Receive all future signals for Earnings Report in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
